Status:
RECRUITING
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
Lead Sponsor:
University of Miami
Collaborating Sponsors:
Eurofins Viracor, LLC
Conditions:
Lung Diseases
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response ...
Eligibility Criteria
Inclusion
- Adult patients over 18 years of age
- Lung transplant candidates with positive CMV IgG
- Anticipated to receive a lung transplant (both double lung and single lung)
Exclusion
- Negative CMV IgG prior transplant
- Pregnant or breastfeeding women
- HIV infected patients
- Combined organ (e.g., lung-heart, lung-kidney) transplant candidates
Key Trial Info
Start Date :
December 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06494033
Start Date
December 3 2024
End Date
June 30 2026
Last Update
March 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136